Literature DB >> 18186008

["Numb chin syndrome": first presenting syndrome of multiple sclerosis?].

A Oestmann1, L Achtnichts, L Kappos, A Gass, Y Naegelin.   

Abstract

HISTORY AND CLINICAL
FINDINGS: A 34-year-old previously healthy woman presented with a five-day history of subacute onset of a numb chin. Examination on admission revealed isolated hypesthesia on the left side of the chin and lower lip. INVESTIGATIONS: Brain magnetic resonance imaging (MRI) demonstrated a lesion involving the pontine trigeminal fibers and multiple periventricular T2-hyperintense white matter lesions suggestive of inflammatory /demyelinating disease. Cerebrospinal fluid analysis revealed oligoclonal IgG bands (only in cerebrospinal fluid) and an increased IgG index. A follow-up MRI after four months demonstrated new supratentorial brain lesions, confirming a syndrome, highly suggestive of multiple sclerosis as the likely underlying diagnosis. TREATMENT AND FOLLOW-UP: The facial sensory disturbance resolved spontaneously. Prophylactic treatment with interferon-beta was started.
CONCLUSION: The numb chin syndrome may be the initial presentation of a clinically isolated syndrome suggestive of multiple sclerosis. Prophylactic immunomodulatory treatment may be started after the suspicion of inflammatory/demyelinating activity is confirmed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18186008     DOI: 10.1055/s-2008-1017477

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  2 in total

1.  Numb Chin Syndrome Leading to a Diagnosis of Salivary Ductal Adenocarcinoma: A Case Report and Review of the Literature.

Authors:  Lei Wu; Yifan Zheng; Zhou Zhou; Yanmei Liu; Weixi Zhang; Qi Wu
Journal:  Front Neurol       Date:  2017-07-25       Impact factor: 4.003

2.  A case report: Numb Chin Syndrome due to thalamic infarction: a rare case.

Authors:  Florian Rimmele; Henning Maschke; Annette Großmann; Tim P Jürgens
Journal:  BMC Neurol       Date:  2019-11-29       Impact factor: 2.474

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.